GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tactile Systems Technology Inc (NAS:TCMD) » Definitions » GF Value
中文

Tactile Systems Technology (Tactile Systems Technology) GF Value : $17.92 (As of Apr. 24, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Tactile Systems Technology GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

  1. Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
  2. GuruFocus adjustment factor based on the company’s past returns and growth.
  3. Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-04-24), Tactile Systems Technology's share price is $15.04. Tactile Systems Technology's GF Value is $17.92. Therefore, Tactile Systems Technology's Price-to-GF-Value for today is 0.84.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Tactile Systems Technology is Modestly Undervalued.


Tactile Systems Technology  (NAS:TCMD) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)Predictable Companies that possibly be Value Traps
Significantly OvervaluedPredictable Companies which are Significantly Overvalued
Modestly OvervaluedPredictable Companies which are Modestly Overvalued
Fairly ValuedPredictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Tactile Systems Technology's Price-to-GF-Value for today is calculated as

Price-to-GF-Value=Share Price/GF Value
=15.04/17.92
=0.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tactile Systems Technology GF Value Related Terms

Thank you for viewing the detailed overview of Tactile Systems Technology's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Tactile Systems Technology (Tactile Systems Technology) Business Description

Traded in Other Exchanges
Address
3701 Wayzata Boulevard, Suite 300, Minneapolis, MN, USA, 55416
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
Executives
Boyd Vindell Washington director 1331 TYLER STREET NE, STE 200, MINNEAPOLIS MN 55413
Daniel L. Reuvers director, officer: President and CEO INTEGRA LIFESCIENCES CORPORATION, 311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Sherri Lee Ferstler officer: Senior VP, Sales 1331 TYLER STREET NE, STE 200, MINNEAPOLIS MN 55413
William W Burke director 3868 MOCKINGBIRD LN, DALLAS TX 75205
Kristie Burns officer: Sr. VP Mktg & Clinical Affairs 3701 WAYZATA BLVD, MINNEAPOLIS MN 55416
Eric Pauls officer: Senior VP, Sales 3701 WAYZATA BLVD, SUITE 300, MINNEAPOLIS MN 55416
Elaine M. Birkemeyer officer: Chief Financial Officer 3701 WAYZATA BLVD, SUITE 300, MINNEAPOLIS MN 55416
Brent Moen officer: Chief Financial Officer 3600 HOLLY LANE NORTH, SUITE 40, PLYMOUTH MN 55447
Carmen B Volkart director C/O MODULAR MEDICAL, INC., 16772 WEST BERNARDO DRIVE, SAN DIEGO CA 92127
Valerie L. Asbury director 3701 WAYZATA BLVD, SUITE 300, MINNEAPOLIS MN 55416
David Brent Shafer director 2800 ROCKCREEK PARKWAY, NORTH KANSAS CITY MO 64117
Bryan Rishe officer: Vice President, Sales 1331 TYLER STREET NE, SUITE 200, MINNEAPOLIS MN 55413
Deepti Jain director 3701 WAYZATA BLVD, MINNEAPOLIS MN 55416
Sheri Louise Dodd director 3701 WAYZATA BLVD, SUITE 300, MINNEAPOLIS MN 55416
Gerald R. Mattys director, officer: Chief Executive Officer 1331 TYLER STREET NE, SUITE 200, MINNEAPOLIS MN 55413